GSK, RSV and Shingles
GSK's RSV, Shingles vaccines show on-par immune response in joint trial
(Reuters) -British drugmaker GSK said on Wednesday administration of its respiratory syncytial virus (RSV) vaccine and shingles shot together generated the same immune response in a late-stage trial as separate adminstration of the vaccines.
GSK Meets Study Goal for Co-Administered RSV-Shingles Vaccines
GSK plc GSK announced positive topline results from a phase III study evaluating the co-administration of its two marketed vaccines — RSV vaccine Arexvy and shingles vaccine Shingrix — in older adults (aged 50 years and older).
GSK Reports Findings on Coadministered RSV and Shingles Vaccines
Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.
GSK Builds Combo Case for RSV, Shingles Shots With Phase III Data
If approved, the co-administration of Arexvy and Shingrix could provide a more convenient vaccination regimen for patients and potentially bolster GSK’s faltering sales for both vaccines.
GSK's Respiratory Syncytial Virus Vaccine Given Together With Shingles Shot Shows Non-Inferior Immune Response In Older Adults
GSK plc (NYSE:GSK) released topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, reactogenicity and safety of Arexvy (Respiratory Syncytial Virus Vaccine) when co-administered with Shingrix (Zoster Vaccine).
GSK touts co-administration data for RSV, shingles vaccines as narrowed CDC guidance threatens sales
In the study, co-administration of GSK's RSV vaccine Arexvy and shingles shot Shingrix elicited non-inferior immune responses compared with separate administration of the vaccines.
GSK Sees Positive Results in Trial of Combination RSV, Shingles Vaccine
GSK recorded positive topline data in a late stage trial of its respiratory syncytial virus vaccine combined with a shingles vaccine in treating adults 50 years and older.
GSK Reports Positive Data From Co-administration Of RSV And Shingles Vaccines
GSK plc (GSK, GSK.L) announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the
CBC.ca4d
Canada approved multiple RSV shots to ward off infections this fall — here's how to get them
Here's what Canadians need to know: Older adults now have access to two approved vaccines, called Arexvy and Abrysvo.
The American Journal of Managed Care4d
New RSV Vaccine Is Likely Cost-Effective for Older Adults, Study Finds
Respiratory syncytial virus (RSV) vaccination in adults aged 60 years and older may be cost-effective in preventing illness, ...
Health.com on MSN8d
Guide to 2024 Fall Vaccines: When to Get Your COVID, Flu, and RSV Shots
Vaccines for the Fall and Winter 2024–2025 season are now available. Generally, experts recommend COVID-19 and flu vaccines ...
Nasdaq2d
GSK Meets Study Goal for Co-Administered RSV-Shingles Vaccines
GSK plc GSK announced positive topline results from a phase III study evaluating the co-administration of its two marketed vaccines — RSV vaccine Arexvy and shingles vaccine Shingrix — in ...
Monthly Prescribing Reference3d
GSK Reports Findings on Coadministered RSV and Shingles Vaccines
Findings showed a noninferior immune response for both vaccines when coadministered compared with separate administration. Topline results were announced from a phase 3 study assessing the immune ...